Global Leading Market Research Publisher QYResearch announces the release of its latest report “CD115 Antibody – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global CD115 Antibody market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for CD115 Antibody was estimated to be worth US28millionin2025andisprojectedtoreachUS28millionin2025andisprojectedtoreachUS42 million by 2032, growing at a CAGR of 6.0% from 2026 to 2032. For immunology researchers, cancer biologists, and bone biology scientists, the core business imperative lies in selecting CD115 antibodies that address the critical need for detecting and quantifying colony-stimulating factor 1 receptor (CSF-1R, also known as macrophage colony-stimulating factor receptor (M-CSFR), CD115, c-fms), a cell surface receptor tyrosine kinase expressed on monocytes/macrophages, peritoneal exudate cells, plasmacytoid dendritic cells, Langerhans cells, microglia (CNS), and osteoclasts. CSF-1R signaling regulates survival, proliferation, differentiation of mononuclear phagocyte lineage (macrophages, osteoclasts, microglia), and is implicated in cancer (tumor-associated macrophages (TAMs)) and inflammatory diseases (rheumatoid arthritis, atherosclerosis). CD115 antibody (clone AFS98) is a rat monoclonal antibody that recognizes mouse CD115 (CSF-1R) and is used for Flow Cytometry, Immunohistochemistry (IHC), Immunofluorescence (IF), Immunoprecipitation (IP), Western Blot (WB), and ELISA. Applications: immunology (macrophage/microglia biology), oncology (CSF-1R inhibition, TAM depletion), osteoporosis (osteoclast differentiation), neuroinflammation (Alzheimer’s microglia). Types: monoclonal (clone AFS98, high specificity) and polyclonal (rabbit, goat, higher sensitivity).
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/releases/5985634/cd115-antibody
The CD115 Antibody market is segmented as below:
Thermo Fisher Scientific
BosterBio
Bioss
BD Biosciences
RayBiotech
BioLegend
LifeSpan BioSciences
Bio-Rad
Antigenix America
Leinco Technologies
Novus Biologicals
Tonbo Biosciences
ichorbio
R&D Systems
AffinityImmuno
Proteintech Group
GeneTex
Biobyt
Jingjie PTM BioLab
Segment by Type
Monoclonal
Polyclonal
Segment by Application
Immunochemistry (IHC)
Immunofluorescence (IF)
Immunoprecipitation (IP)
Western Blot (WB)
ELISA
Others
1. Market Drivers: Immuno-Oncology, Macrophage Biology, and Bone Research
Several powerful forces are driving the CD115 antibody market:
Immuno-oncology and tumor-associated macrophages (TAMs) – CSF-1R inhibitors (pexidartinib (Turalio), BLZ945, ARRY-382) clinical trials for cancer (glioblastoma, breast, pancreatic). CD115 antibody for IHC detection of TAM infiltration in tumors (prognosis, response to therapy).
Macrophage and microglia research – CSF-1R signaling essential for microglia survival (brain, CNS). Alzheimer’s disease, multiple sclerosis. Antibody for IHC, IF of brain tissue.
Osteoclast differentiation and bone biology – CSF-1R (M-CSFR) required for osteoclast differentiation (bone resorption). Osteoporosis, rheumatoid arthritis research. Antibody for IHC of bone sections.
Recent market data (December 2025): According to Global Info Research analysis, monoclonal CD115 antibodies dominate with approximately 65% revenue share (clone AFS98 (mouse) superior specificity, less background). Polyclonal 35% share (higher sensitivity, broader reactivity). Immunohistochemistry (IHC) largest application (35% share) (TAM staining, bone marrow). Flow Cytometry (included Others) 25% share (cell surface staining). Western Blot (WB) 20% share. Immunofluorescence (IF) 10% share. Immunoprecipitation (IP) 5% share. ELISA 5% share. North America largest market (45% share) (NIH, biotech immuno-oncology). Europe 30% share. Asia-Pacific 20% share. BioLegend (US), BD Biosciences (US), R&D Systems (US) leading suppliers of AFS98 clone.
2. Antibody Types and Specifications
| Type | Clone | Host | Species Reactivity | Applications | Price | Share |
|---|---|---|---|---|---|---|
| Monoclonal | AFS98 | Rat | Mouse | FC, IHC, IF, IP, WB | US$300-500 | ~65% |
| Polyclonal | N/A | Rabbit, goat | Mouse, human, rat | WB, IHC, ELISA | US$200-400 | ~35% |
Key specifications: Target (CD115, CSF-1R, M-CSFR, c-fms). Clone (AFS98). Host (rat IgG2a). Reactivity (mouse, also human cross-reactive). Applications validated (FC (Flow Cytometry), IHC (frozen, paraffin), IF, IP, WB, ELISA). Conjugation (unconjugated, FITC, PE, APC, Biotin, HRP). Concentration (0.5-1 mg/mL). Format (liquid, lyophilized, azide-free). Storage (4°C, -20°C, -80°C). Positive control (bone marrow, spleen, peritoneal macrophages, RAW 264.7 cell line). Clone AFS98 from BioLegend, BD Biosciences, eBioscience (Thermo Fisher).
Exclusive observation (Global Info Research analysis): The CD115 antibody market is dominated by clone AFS98 (BioLegend, BD Biosciences, Thermo Fisher) for mouse studies. Human CD115 antibodies (clone 9-4D2 (BioLegend), 61703 (R&D Systems)) also available. Polyclonal rabbit antibodies (Proteintech, GeneTex, Bioss) for western blot, IHC, broader reactivity. Multi-color flow cytometry panels require conjugated antibodies (FITC, PE, APC, PerCP-Cy5.5, BV421). Chinese suppliers (Bioss, Biobyt, Jingjie) lower cost domestic.
User case – Immunohistochemistry (IHC) (December 2025): Cancer research lab (US) stains mouse tumor xenograft (breast cancer) for CD115 (AFS98) to visualize TAM infiltration. FFPE (Formalin-Fixed Paraffin-Embedded) sections, antigen retrieval (citrate), primary antibody (BioLegend CD115 (AFS98), 1:100), secondary HRP-polymer, DAB detection. Counterstain hematoxylin. Image quantification.
User case – Flow Cytometry (January 2026): Immunology lab (Europe) characterizes bone marrow-derived macrophages (BMDM). Cells harvested, blocked (Fc block), stained with CD115-PE (BD Biosciences AFS98-PE, 1:200). Flow cytometry, gating CD115+ macrophages. TAM depletion experiment.
3. Technical Challenges
Species cross-reactivity – AFS98 (rat anti-mouse) minimal cross-reactivity to human CD115. Human studies require human-specific CD115 antibody (clone 9-4D2, 61703). Polyclonal rabbit may cross-react.
Tissue autofluorescence in IHC/IF – Macrophage-rich tissues (liver, spleen, lung) autofluorescence. Blocking (Sudan Black, TrueBlack). Antibody conjugation (AF647, AF568).
Technical difficulty – formalin-fixed paraffin-embedded (FFPE) IHC optimization: CD115 (CSF-1R) antigen retrieval, epitope unmasking. Prolonged 0.01M citrate buffer pH 6.0, 95°C. Clone AFS98 validated for frozen but FFPE optimization required.
Technical development (October 2025): BioLegend (US) introduced recombinant rabbit monoclonal CD115 antibody (clone not disclosed) for human and mouse IHC (FFPE), WB (Western Blot), FC. Higher specificity, consistent batch-to-batch, no animal-derived. Price premium (US400vsUS400vsUS350).
4. Competitive Landscape
Key players include: Thermo Fisher Scientific (US – eBioscience, Invitrogen), BosterBio (US), Bioss (China), BD Biosciences (US – AFS98), RayBiotech (US), BioLegend (US – AFS98 leader), LifeSpan BioSciences (US), Bio-Rad (US – antibodies), Antigenix America (US), Leinco Technologies (US), Novus Biologicals (US), Tonbo Biosciences (US), ichorbio (UK), R&D Systems (US (Bio-Techne) – MAB2315 human), AffinityImmuno (US), Proteintech Group (US/China), GeneTex (US), Biobyt (China), Jingjie PTM BioLab (China). BioLegend, BD Biosciences, R&D Systems dominant for AFS98.
Regional dynamics: North America (BioLegend, BD, R&D Systems, Thermo Fisher) largest market. Europe (BioLegend distribution, ichorbio). China (Bioss, Proteintech China, Biobyt, Jingjie) domestic.
5. Outlook
CD115 antibody market will grow at 6.0% CAGR to US$42 million by 2032, driven by immuno-oncology (TAM targeting), macrophage biology, and CSF-1R inhibitor research. Technology trends: recombinant monoclonal (consistent, animal-free), multiplex immunohistochemistry (mIHC) (spatial phenotyping), and spatial transcriptomics (FFPE optimization). Asia-Pacific growth 7-8% CAGR. Conjugated antibodies (PE, APC, BV421) for high-parameter flow cytometry growing.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
